-
Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery
•
Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi Holdings Limited (HKG: 2228), a global leader in AI+ automation technology platforms. This investment will fuel the deep integration of Newdel Biotech’s DNA-encoded compound library (DEL) technology with XtalPi’s AI platform, aiming to accelerate the…
-
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
•
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8 million) via a Pre-Series A financing round. Led by Growth FoF, the funding included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group, Henry WU, and Shanghai Healthcare Capital, among others. The proceeds will be…
-
Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9 billion (USD537 million) through a private placement. The funds will be allocated to various novel drug research and development programs, furthering the company’s commitment to innovation in the biopharmaceutical sector. Funding AllocationThe proceeds from the…
-
Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million (USD17.9 million) in compatriot firm Shenzhen GeneMind Biosciences Co., Ltd., a gene sequencer specialist. This investment aims to enhance Sansure’s industry chain layout in the gene sequencing sector and boost its comprehensive competitiveness. Transaction DetailsThe…
-
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
•
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of US-headquartered Checkpoint Therapeutics (NASDAQ: CKPT) for USD4.1 per share, totaling USD355 million. As part of the deal, Checkpoint shareholders will receive a contingent value right (CVR) entitling them to up to USD0.70 per share, contingent…
-
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
•
NewCo is a new transaction model developed by Chinese innovative drug companies in response to capital winter and internationalization needs. It involves licensing overseas rights of early-stage R&D pipelines to newly established independent companies, bringing in overseas capital and management teams to accelerate development and share risks. This model combines…
-
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
•
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s “4+1” Biomedical and High-end Medical Device Industry Fund and Qihang Investment Management Co., Ltd., with Lighthouse Capital serving as the exclusive financial advisor. The funds will propel the Phase III clinical trial of CXG87, a…
-
4C Medical Lands $175M Series D to Advance AltaValve TMVR System
•
US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), announced the completion of a $175 million Series D financing round. The funding, led by Boston Scientific Corporation, will accelerate clinical development and commercialization of 4C Medical’s AltaValve System, a next-generation…
-
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
•
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…
-
Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline
•
Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB 150 million (USD 21 million) in a new financing round. The round was led by Bayland Capital and included contributions from AstraZeneca-CICC Health Industry Investment Fund, Growth Investment, Panlin Capital, and returning investor Sequoia Capital.…
-
Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion
•
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Qiming Venture Partners and Lilly Asia Ventures, with contributions from returning investors OrbiMed and Gaorong Capital. Company…
-
Biointron Biologics Files for Public Offering, Aims for BSE Listing
•
On February 11, Biointron Biologics released its tutoring filing report for the public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange (BSE). The tutoring work is led by Haitong Securities Co., Ltd., with Grandway Law Offices and Grant Thornton China (Special General Partnership) responsible…
-
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
•
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical manufacturing sites in the United States. The move aims to boost the company’s domestic medicine production across various therapeutic areas. API Manufacturing and Supply Chain StrengtheningThree of the new sites will focus on manufacturing active…
-
CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership) to jointly invest in its subsidiary UCARsgen Biotech Limited. UCARsgen focuses on developing allogeneic CAR-T cell therapies for hematologic malignancies. Deal Highlights
-
Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
•
China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8 million) in a Series A financing round led by SDIC. The AstraZeneca-CICC Medical Industry Investment Fund, an existing investor, also participated. The proceeds will fund clinical filings, development of core pipelines, and expansion of the…
-
Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech
•
Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and laser ablation, has reportedly raised over RMB 100 million (USD 13.8 million) in a new financing round. Investors include Nanjing NII Group, Huatai Zijin, Peiyang Begonia Fund, Andon Health, and bioVenture, with Starboard Value serving…
-
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
•
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China subsidiary to UK-based AstraZeneca (NASDAQ: AZN) for approximately USD160 million. The deal includes the transfer of all rights to roxadustat, a treatment for anemia caused by chronic kidney disease (CKD), in China. Transaction DetailsUnder the…
-
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
•
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States related to recent legal issues in China, including the arrest of its former China market president, Leon Wang. The lawsuits allege that the UK-based pharmaceutical giant made misleading statements about its operations in China, failing…
-
Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round
•
Weimai Qingtong Medical Technology (WEMT), a medical device company based in Wuxi, has completed a B+ financing round worth tens of millions of yuan. The round was led by Wuxi Capital Group Co., Ltd. and Jinsheng Capital, with WinX Capital serving as the exclusive financial advisor. The funds will be…
-
Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
•
Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million (USD13.7 million) in a Series B financing round co-led by Lapam Capital and Shanghai Healthcare Capital. The funds will support the commercial expansion of its core products, particularly in the US and China, as well…
